Drug
Allo 715
Allo 715: highest development phase Phase 1, developed by Allogene Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Allogene Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALLO-715 NCT04093596 | Phase 1 | Relapsed/Refractory Multiple Myeloma |
Latest
No recent events.
Follow Allo 715 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.